The proposed event-driven approach for Bayesian two-stage single-arm phase II trial design is a novel clinical trial design and can be regarded as an extension of the Simon’s two-stage design with the time-to-event endpoint. This design is motivated by cancer clinical trials with immunotherapy and molecularly targeted therapy, in which time-to-event endpoint is often a desired endpoint.
|Author||Chia-Wei Hsu [aut, cre], Haitao Pan [aut], Jianrong Wu [aut]|
|Maintainer||Chia-Wei Hsu <Chia-Wei.Hsu@stjude.org>|
|Package repository||View on CRAN|
Install the latest version of this package by entering the following in R:
Any scripts or data that you put into this service are public.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.